503 KH-801, a differentated humanized anti-CD24 antibody, potentiates the effects of immunomodulatory and anti-tumor activity in preclinical cancer models with favorable safety profiles

• Xiao Ke,
• Pengfei Wu,
• Yonghao Zhao,
• Pengfei Ren,
• Gang Lei,
• Menglong Guan,
• Ju Yue,
• Jichao Wang,
• Yanhua Xu

Affiliations

Xiao Ke

22 Medical Research Center, Chengdu Kanghong Biotechnology Inc, Chengdu, Sichuan, China

Pengfei Wu

2Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China

Yonghao Zhao

2Sichuan Provincial Key Laboratory of Biomacromolecular Protein Drugs, Chengdu, Sichuan, China

Pengfei Ren

1Chengdu Kanghong Pharmaceutical Group, Chengdu, Sichuan, China

Gang Lei

1Chengdu Kanghong Pharmaceutical Group, Chengdu, Sichuan, China

Menglong Guan

1Chengdu Kanghong Pharmaceutical Group, Chengdu, Sichuan, China

Ju Yue

1Chengdu Kanghong Pharmaceutical Group, Chengdu, Sichuan, China

Jichao Wang

1Chengdu Kanghong Pharmaceutical Group, Chengdu, Sichuan, China

Yanhua Xu

1Chengdu Kanghong Pharmaceutical Group, Chengdu, Sichuan, China